Prophylaxis News and Research

RSS

Baxter receives FDA approval for ADVATE to prevent hemophilia A

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A.

From Baxter International Inc. 17 Dec 2011

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.

17 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

Global plan of action needed to end AIDS

After "President Obama threw the full weight of the U.S. government behind a vision" to end the AIDS epidemic in a World AIDS Day speech, "[n]ow the question is: How will we achieve this goal? What are the priority actions to take today, tomorrow, and years from now?" Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, writes in the Huffington Post's "Impact" blog.

8 Dec 2011

PrEP shows promise against HIV infection

A new weapon has emerged to prevent HIV infection. Called pre-exposure prophylaxis, or PrEP, it is a strategy of providing medications to at-risk people before they are exposed to the virus. Having shown great promise in recent phase 3 clinical trials, PrEP may soon be rolled out for public use.

8 Dec 2011

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

1 Dec 2011

Duplex ultrasound screening can detect high rate of LDVT's in critically ill trauma patients

A study published in the September 2011 issue of the Journal of Vascular Surgery®, the official publication of the Society for Vascular Surgery®, reports that a high rate of lower deep vein thromboses (LDVT's) in critically ill trauma cases can be detected through duplex ultrasound screening (DUS).

1 Dec 2011

VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa

VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - has stopped testing the gel.

29 Nov 2011

Recent scientific progress in developing new HIV/AIDS interventions

Kaitlin Christenson, coalition director for the Global Health Technologies Coalition, "reflects on recent progress made by the scientific community in developing new interventions to combat HIV/AIDS as a result of leadership from the U.S. government" in this ONE blog post.

19 Nov 2011

HVTN debunks top 10 myths about HIV vaccine research

Dec. 1 is World AIDS Day, and in commemoration of the occasion, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, debunks the top 10 myths about HIV vaccine research.

18 Nov 2011

Public health officials should address needs of people with blood disorders

Public health should focus not only on reducing the burden of common diseases but also address the needs of people with blood disorders , experts say in a supplement to December's American Journal of Preventive Medicine.

16 Nov 2011

$New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout$

New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout

Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.

7 Nov 2011

AHA/ASA honors UH Case Medical Center with Get With The Guidelines-Stroke award

For the third consecutive year, University Hospitals (UH) Case Medical Center has received the American Heart Association/American Stroke Association's Get With The Guidelines--Stroke Gold Plus Quality Achievement Award.

4 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.